Incidence of gastrointestinal perforation associated with bevacizumab in combination with neoadjuvant chemotherapy as first-line treatment of advanced ovarian, fallopian tube, or peritoneal cancer: analysis of a Japanese healthcare claims database

OBJECTIVE: To assess the incidence of bevacizumab-associated gastrointestinal (GI) perforation during first-line treatment of patients with ovarian, fallopian tube, or peritoneal cancer receiving neoadjuvant chemotherapy (NAC) in Japanese real-world clinical practice. METHODS: A retrospective study...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueda, Akihiko, Watari, Hidemichi, Mandai, Masaki, Fukuhara, Shunichi, Sugitani, Yasuo, Ogino, Kiyoko, Kamijima, Shuichi, Enomoto, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634096/
https://www.ncbi.nlm.nih.gov/pubmed/36245228
http://dx.doi.org/10.3802/jgo.2022.33.e78

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634096/
https://www.ncbi.nlm.nih.gov/pubmed/36245228
http://dx.doi.org/10.3802/jgo.2022.33.e78

Ejemplares similares